Stem Cells And Myocardial Regeneration by Marc S. Penn , Humana Press Inc.

Description

Humana Press Inc. Stem Cells And Myocardial Regeneration by Marc S. Penn

Over the past 5 years there has been great excitement and controversy in the scientific, financial, and lay literature for the potential of stem cell-based strategies for the prev- tion and treatment of chronic heart failure (CHF). Not that long ago we believed we were born with a set number of cardiac myocytes and that once damaged there was no hope to replace them. The interest in the field stems from the magnitude of cardiovascular disease in the world. Our ability to treat and help patients survive acute myocardial infarction (MI) has resulted in a near epidemic of CHF. There are more than 5 million Americans who currently carry the diagnosis of CHF. With more than 1 million MIs a year in the United States, there are approx 500,000 new cases of CHF diagnosed each year. The goal of Stem Cells and Myocardial Regeneration is to present, in a coherent manner, the current state of knowledge of stem cell-based therapies for cardiac dysfunction, including current findings in both the laboratory and the clinic trials. The first section of this Stem Cells and Myocardial Regeneration focuses on the magnitude of the problem and the successes and failures of what we consider optimal medical therapy. It is on this background that stem cell-based therapy needs to build._x000D_ _x000D_ Stem Cells and Myocardial Regeneration_x000D_ _x000D_ Table of Contents_x000D_ _x000D_ 1. The Challenge for Stem Cell Therapy: Overview of the Problem: Heart Attack and Heart Failure_x000D_ Marc S. Penn, MD, PhD_x000D_ Eric J. Topol, MD_x000D_ Cleveland Clinic Foundation_x000D_ _x000D_ Cells of interest for myocardial regeneration_x000D_ 2. Hematopoietic Stem Cells for Myocardial Regeneration_x000D_ Don Orlic, PhD_x000D_ Richard O. Cannon III, M.D._x000D_ National Institutes of Health_x000D_ _x000D_ 3. Mesenchymal Stem Cells for Cardiac Therapy_x000D_ Mark F. Pittenger, PhD_x000D_ Osiris Therapeutics, Inc_x000D_ _x000D_ 4. Multipotent Adult Progenitor Cells_x000D_ Wouter van't Hof_x000D_ Niladri Mal_x000D_ Amy Raber_x000D_ Ming Zhang_x000D_ Anthony Ting_x000D_ Marc S. Penn_x000D_ Robert Deans_x000D_ Athersys_x000D_ _x000D_ 5. Mesenchymal Progenitor Cells for Vascular Formation and Cardiac Muscle Regeneration_x000D_ Silviu Itescu MD_x000D_ Fiona See PhD_x000D_ Timothy Martens MD_x000D_ Columbia University_x000D_ _x000D_ 6. Umbilical Cord Blood Stem Cells for Myocardial Regeneration and Angiogenesis_x000D_ Shyam Bhakta, MD_x000D_ Mary Laughlin, MD_x000D_ Case Western Reserve University_x000D_ _x000D_ 7. Endogenous Cardiac Stem Cells_x000D_ Elisa Messina_x000D_ Alessandro Giacomello_x000D_ Eduardo Marban_x000D_ University of Rome 'La Sapienza' & Johns Hopkins University_x000D_ _x000D_ 8. Embryonic Stem Cells for Myocardial Repair_x000D_ Lior Gepstein, MD, PhD_x000D_ Technion, Israel_x000D_ _x000D_ Mechanisms and critical pathways involved in myocardial repair_x000D_ 9. Chemokine and Homing Factor Expression in Acute Myocardial Infarction and Congestive Heart Failure _x000D_ Arman T. Askari, MD _x000D_ Marc S. Penn, MD, PhD_x000D_ Cleveland Clinic Foundation_x000D_ _x000D_ 10. Stem Cell Differentiation Towards a Cardiac Myocyte Phenotype_x000D_ Andrea Ladd, PhD_x000D_ Cleveland Clinic Foundation_x000D_ _x000D_ 11. Electrical Coupling and/or Ventricular Tachycardia Risk of Cell Therapy_x000D_ Shuixiang Yang MD_x000D_ Dayi Hu, MD, PhD_x000D_ Beijing, China_x000D_ _x000D_ 12. Cell Therapy for Myocardial Damage: Arrhythmia Risk and Mechanisms_x000D_ William R. Mills, MD_x000D_ Kenneth R. Laurita, PhD_x000D_ MetroHealth Campus, Case Western Reserve University_x000D_ _x000D_ Strategies for Cell Delivery advantages/disadvantages_x000D_ 13. Aspects of Percutaneous Cellular Cardiomyoplasty_x000D_ Matthew Hook, MD_x000D_ Patrick Whitlow, MD_x000D_ Cleveland Clinic Foundation_x000D_ _x000D_ 14. Open-Chest / Minimally Invasive Surgical Techniques_x000D_ Roberto Lorusso MD, PhD_x000D_ Jose L. Navia, MD_x000D_ Cesare Beghi Degrees, MD_x000D_ Fernando A. Atik, MD_x000D_ Cleveland Clinic Foundation, Brescia and Parma, Italy_x000D_ _x000D_ Stem Cell Based Clinical Trials for Cardiac Dysfunction_x000D_ 15. Measures of Effective Cell Based Therapies_x000D_ Wael A. Jaber, MD_x000D_ Manuel Cerqueira, MD_x000D_ Cleveland Clinic Foundation_x000D_ _x000D_ Congestive Heart Failure_x000D_ 16. Whole Bone Marrow Transplantation_x000D_ Emerson C. Perin, MD_x000D_ Guilherme V. Silva, MD _x000D_ Texas Heart Institute_x000D_ _x000D_ 17. Clinical Angioblast Therapy_x000D_ Amit N. Patel, MD, MS_x000D_ Jorge Genovese, MD_x000D_ University of Pittsburgh Medical Center_x000D_ _x000D_ 18. Use of skeletal myoblasts for the treatment of CHF_x000D_ Anthony W. Ashton_x000D_ David D'Alessandro_x000D_ Robert E. Michler_x000D_ Albert Einstein College_x000D_ _x000D_ Acute MI _x000D_ 19. Bone Marrow and Angioblast Transplantation_x000D_ Marc S. Penn, MD, PhD_x000D_ Samuel Unzek, MD_x000D_ Niladri Mal, MD_x000D_ Kai Wang, MD, PhD_x000D_ Cleveland Clinic Foundation_x000D_ _x000D_ 20. Strategies for Cytokine Modification and Stem Cell Mobilization_x000D_ Stephen G. Ellis, MD_x000D_ Brian J. Bolwell, MD_x000D_ Cleveland Clinic Foundation_x000D_ _x000D_ Summary/Future Challenges_x000D_ 21 Summary and Future Challenges_x000D_ Marc S. Penn, MD, PhD_x000D_ Cleveland Clinic Foundation_x000D_